ZNTL – Zentalis Pharmaceuticals, Inc.
ZNTL — Price & Forward EBITDA
Forward EBITDA (M)
Float Short %
8.57
Margin Of Safety %
Put/Call OI Ratio
0.12
EPS Next Q Diff
-0.07
EPS Last/This Y
0.21
EPS This/Next Y
Price
2.68
Target Price
5.31
Analyst Recom
2.11
Performance Q
94.89
Upside
-2,603.7%
Beta
1.54
Ticker: ZNTL
of 1
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2026-03-09 | ZNTL | 2.48 | 0.12 | 0.00 | 5052 |
| 2026-03-10 | ZNTL | 3.06 | 0.11 | 0.00 | 5111 |
| 2026-03-11 | ZNTL | 2.97 | 0.08 | 0.06 | 6826 |
| 2026-03-12 | ZNTL | 2.76 | 0.08 | 0.00 | 7072 |
| 2026-03-13 | ZNTL | 2.75 | 0.08 | 0.00 | 7072 |
| 2026-03-17 | ZNTL | 2.74 | 0.08 | 0.00 | 7105 |
| 2026-03-18 | ZNTL | 2.52 | 0.08 | 1.83 | 7123 |
| 2026-03-19 | ZNTL | 2.57 | 0.08 | 5.00 | 7129 |
| 2026-03-20 | ZNTL | 2.61 | 0.09 | 0.00 | 7140 |
| 2026-03-23 | ZNTL | 2.55 | 0.05 | 77.00 | 4553 |
| 2026-03-24 | ZNTL | 2.47 | 0.05 | 0.04 | 4545 |
| 2026-03-25 | ZNTL | 2.56 | 0.05 | 0.33 | 5270 |
| 2026-03-26 | ZNTL | 2.68 | 0.05 | 0.33 | 5270 |
| 2026-03-27 | ZNTL | 2.11 | 0.05 | 6.23 | 5290 |
| 2026-03-30 | ZNTL | 2.14 | 0.12 | 0.00 | 5736 |
| 2026-03-31 | ZNTL | 2.35 | 0.12 | 0.00 | 5771 |
| 2026-04-01 | ZNTL | 2.58 | 0.10 | 0.00 | 6761 |
| 2026-04-02 | ZNTL | 2.64 | 0.10 | 0.00 | 6761 |
| 2026-04-06 | ZNTL | 2.69 | 0.10 | 0.57 | 6765 |
| 2026-04-07 | ZNTL | 2.68 | 0.12 | 0.00 | 7197 |
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2026-03-09 | ZNTL | 2.48 | 5.9 | - | -1.76 |
| 2026-03-10 | ZNTL | 3.06 | 5.9 | - | -1.76 |
| 2026-03-11 | ZNTL | 2.96 | 5.9 | - | -1.76 |
| 2026-03-12 | ZNTL | 2.75 | 5.9 | - | -1.76 |
| 2026-03-13 | ZNTL | 2.72 | 5.9 | - | -1.76 |
| 2026-03-17 | ZNTL | 2.74 | 5.9 | - | -1.76 |
| 2026-03-18 | ZNTL | 2.52 | 5.9 | - | -1.76 |
| 2026-03-19 | ZNTL | 2.57 | 5.9 | - | -1.76 |
| 2026-03-20 | ZNTL | 2.61 | 0.4 | - | -1.76 |
| 2026-03-23 | ZNTL | 2.54 | 0.4 | - | -1.76 |
| 2026-03-24 | ZNTL | 2.47 | 0.4 | - | -1.76 |
| 2026-03-25 | ZNTL | 2.56 | 0.4 | - | -1.76 |
| 2026-03-26 | ZNTL | 2.68 | 0.4 | - | -1.76 |
| 2026-03-27 | ZNTL | 2.11 | 0.4 | - | -1.76 |
| 2026-03-30 | ZNTL | 2.15 | 0.4 | - | -1.76 |
| 2026-03-31 | ZNTL | 2.35 | 0.4 | - | -1.76 |
| 2026-04-01 | ZNTL | 2.58 | 0.4 | - | -1.76 |
| 2026-04-02 | ZNTL | 2.64 | 0.4 | - | -1.76 |
| 2026-04-06 | ZNTL | 2.69 | 20.9 | - | -1.70 |
| 2026-04-07 | ZNTL | 2.68 | 20.9 | - | -1.70 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2026-03-09 | ZNTL | -4.61 | -17.42 | 7.62 |
| 2026-03-10 | ZNTL | -4.61 | -17.42 | 7.62 |
| 2026-03-11 | ZNTL | -4.61 | -17.42 | 7.62 |
| 2026-03-12 | ZNTL | -4.61 | -17.42 | 7.62 |
| 2026-03-13 | ZNTL | -4.61 | -17.42 | 7.62 |
| 2026-03-17 | ZNTL | -4.61 | -17.41 | 7.62 |
| 2026-03-18 | ZNTL | -4.61 | -17.41 | 7.62 |
| 2026-03-19 | ZNTL | -4.61 | -17.41 | 7.62 |
| 2026-03-20 | ZNTL | -4.61 | -17.41 | 7.62 |
| 2026-03-23 | ZNTL | -4.61 | -17.41 | 7.62 |
| 2026-03-24 | ZNTL | -4.61 | -17.41 | 7.62 |
| 2026-03-25 | ZNTL | -4.61 | -17.41 | 8.41 |
| 2026-03-26 | ZNTL | -4.61 | -17.41 | 8.41 |
| 2026-03-27 | ZNTL | -4.61 | -17.41 | 8.41 |
| 2026-03-30 | ZNTL | -4.69 | -17.68 | 8.57 |
| 2026-03-31 | ZNTL | -4.69 | -17.68 | 8.57 |
| 2026-04-01 | ZNTL | -4.69 | -17.68 | 8.57 |
| 2026-04-02 | ZNTL | -4.69 | -17.68 | 8.57 |
| 2026-04-06 | ZNTL | -4.69 | -17.68 | 8.57 |
| 2026-04-07 | ZNTL | -4.69 | -17.68 | 8.57 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
-0.49
Avg. EPS Est. Current Quarter
-0.4
Avg. EPS Est. Next Quarter
-0.56
Insider Transactions
-4.69
Institutional Transactions
-17.68
Beta
1.54
Average Sales Estimate Current Quarter
Average Sales Estimate Next Quarter
Fair Value
Quality Score
6
Growth Score
19
Sentiment Score
96
Actual DrawDown %
96.9
Max Drawdown 5-Year %
-98.8
Target Price
5.31
P/E
Forward P/E
PEG
P/S
P/B
0.85
P/Free Cash Flow
EPS
-1.91
Average EPS Est. Cur. Y
-1.7
EPS Next Y. (Est.)
-1.7
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
Relative Volume
0.3
Return on Equity vs Sector %
-90.9
Return on Equity vs Industry %
-74.3
EPS 1 7Days Diff
0.1
EPS 1 30Days Diff
0.13
EBIT Estimation
◆
ZNTL
Healthcare
$2.67
Swing / Pullback
Buy the dip on strong trends
WEAK
RSI
54.2
Range 1M
59.4%
Sup Dist
1.5%
Momentum Growth
Ride accelerating trends
WEAK
EPS Yr
-7.3%
EPS NY
20.5%
52W%
57.5%
Long-Term Value
Quality companies, undervalued
WEAK
🟢 BUY
+98.9% upside
Upside
+98.9%
Quality
6
Zentalis Pharmaceuticals, Inc.Sector: Healthcare
Industry: Biotechnology
Employees: 106
Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers in the United States. The company develops azenosertib, which is in a Phase 3 clinical trial for the treatment of ovarian cancer and other tumor types. It also develops ZN-c3-001, a phase 1 study that evaluated azenosertib monotherapy in solid tumors; and MAMMOTH (ZN-c3-006) is a Phase 1/2 clinical trial of azenosertib in patients with PARP-inhibitor resistant ovarian cancer. It has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC. Zentalis Pharmaceuticals, Inc. was incorporated in 2014 and is headquartered in San Diego, California.
ZNTL
Latest News
—
Caricamento notizie per ZNTL…
stock quote shares ZNTL – Zentalis Pharmaceuticals, Inc. Stock Price stock today
news today ZNTL – Zentalis Pharmaceuticals, Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch ZNTL – Zentalis Pharmaceuticals, Inc. yahoo finance google finance
stock history ZNTL – Zentalis Pharmaceuticals, Inc. invest stock market
stock prices ZNTL premarket after hours
ticker ZNTL fair value insiders trading